<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640549</url>
  </required_header>
  <id_info>
    <org_study_id>A2581040</org_study_id>
    <nct_id>NCT00640549</nct_id>
  </id_info>
  <brief_title>Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus</brief_title>
  <acronym>ALPIN</acronym>
  <official_title>Impact of Atorvastatin on the Distribution, Composition, and Metabolism of LDL and HDL Subfractions: A Double-Blind Placebo-Controlled Phase IV Study With Patients Suffering From Combined Hyperlipidemia and Diabetes. Atorvastatin and LDL Profile in NIDDM (ALPIN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effects of atorvastatin on the concentrations of small, dense
      LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was terminated on October 6, 2004. The study terminated prematurely because of a
      higher screening failure rate than expected. There were no safety or efficacy reasons
      involved in the decision to terminate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in concentration of HDL subfractions 2a and 2b compared with screening (visit 1)</measure>
    <time_frame>8 weeks (visit 4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in concentration of LDL subfractions LDL-5 and LDL-6 compared with screening (visit 1)</measure>
    <time_frame>8 weeks (visit 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in concentration of apolipoprotein B in VLDL, IDL, LDL-1 through LDL-6 and apolipoprotein A I in HDL subfractions 2a, 2b, and HDL-3 compared with screening (visit 1)</measure>
    <time_frame>8 weeks (visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cholesterol ester transfer protein (CETP), lipoprotein and hepatic lipase activity compared with screening (visit 1)</measure>
    <time_frame>8 weeks (visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in concentration of triglycerides, LDL, and HDL compared with screening (visit 1)</measure>
    <time_frame>8 weeks (visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in size of LDL subfractions compared with screening (visit 1)</measure>
    <time_frame>8 weeks (visit 4)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Non-Insulin Dependent Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lipitor, Sortis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with a diagnosis of type 2 diabetes mellitus who either have
             never had a major adverse cardiac event (MACE) diagnosed before or who had a MACE
             diagnosed at least 6 months ago, but who, according to the judgement of the treating
             general practitioner, do not receive any hyperlipidemic therapy. Major adverse cardiac
             events (MACE) include myocardial infarction, coronary angioplasty, coronary artery
             bypass graft or other revascularization procedures.

        At Screening:

        Visit 1 (week -4):

          1. Male patients aged &gt;35 and ≤75 years and postmenopausal female patients ≤75 years with
             a diagnosis of type 2 diabetes mellitus

          2. Patients have been euthyroid for at least six months

          3. Written informed consent obtained

             At Visit 2 (week 0):

          4. LDL cholesterol ≥130 mg/dl (3.3 mmol/l ) and &lt;190 mg/dl (4.9 mmol/l)

          5. Triglycerides &lt;150 mg/dl (1.69 mmol/l ) and &lt;600 mg/dl (11.3 mmol/l)

          6. Sum of LDL-5 and LDL-6 cholesterol ≥25 mg/dl (0.65 mmol/l)

          7. Follicle stimulating Hormone (FSH) &gt;30 U/l in female patients aged &lt;60 years or FSH
             &gt;20 U/l in female patients aged ≥60 years

        Exclusion Criteria:

          -  HbA1c &gt; 8.0

          -  Creatine kinase (CK) &gt;5 times the upper limit of normal

          -  Patients having taken lipid lowering medication within 8 weeks of the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bad Muenster Am Stein</city>
        <zip>55583</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bosenheim</city>
        <zip>55545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bretten</city>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuenzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rain</city>
        <zip>94369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Schwabenheim</city>
        <zip>55270</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581040&amp;StudyName=Atorvastatin%20and%20LDL%20Profile%20in%20Non-Insulin%20Dependent%20Diabetes%20Mellitus%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>LDL-subfractions, HDL-subfractions, non insulin dependent diabetes mellitus (NIDDM), hyperlipidemia, atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

